Multicenter Phase 2/3 Study of Ficerafusp Alfa With Pembrolizumab in First-Line PD-L1+ HNSCC

Bicara Therapeutics is evaluating the safety and efficacy of ficerafusp alfa—a dual EGFR/TGFβ inhibitor—combined with pembrolizumab versus placebo plus pembrolizumab in first-line treatment of PD-L1-positive recurrent or metastatic head and neck squamous cell carcinoma. This randomized, double-blind study spans multiple dosing arms to determine the optimal regimen for these patients.